StockData
Sagimet Biosciences Inc. logo

Sagimet Biosciences Inc. (SGMT) stock

SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$10.11+0.26 (+2.64%)

Close on Nov 18, 2026Market cap $628.42MP/E –Yield –

Sagimet Biosciences gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Sagimet Biosciences

Sagimet Biosciences has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Sagimet Biosciences figures

See a number that looks wrong?